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Background. The TUNE­IN (The Use of VTE prophylaxis in relatioN to patiEnt risk profiling) study evaluated venous thromboembolism 
(VTE) risk assessment and prophylaxis in private medical and surgical inpatients in Gauteng Province, South Africa. The study concluded 
that of the 608 patients enrolled, 54.1% were clinically evaluated to be at risk for VTE. A VTE risk assessment model (RAM), the Caprini 
score, increased the rate to 74.6%.
Objectives. TUNE­IN Wave 2, an extension of TUNE­IN, was conducted on a national level including the public sector, focusing on surgical 
inpatients.
Methods. The study was a national, prospective, non­interventional, multisite, epidemiological disease registry enrolling 453 surgical 
inpatients. The perceived clinical VTE risk, VTE risk score on Caprini RAM, VTE prophylaxis and clinical details were documented during 
a baseline visit. A bleeding risk score was provided.
Results. Of the cohort, 269 patients (59.4%) were assessed to be at risk for VTE before applying the RAM. All patients (100%), however, were 
at risk on the RAM score. Early mobilisation and assessment of the VTE risk as low were the most frequent reasons for non­prescription of 
prophylaxis. Only 15 patients in the private and 2 in the public sector were assessed as having a bleeding risk. Chemoprophylaxis differed 
between the healthcare sectors, with low­molecular­weight heparin predominating in the private sector and unfractionated heparin being 
prescribed only in the public sector.
Conclusion. VTE risk assessment and prophylaxis need to improve in both the public and the private sectors. A formal RAM will improve 
identification of patients at risk of VTE.
S Afr Med J 2014;104(12):880­884. DOI:10.7196/SAMJ.8456
The ENDORSE (Epidemiologic International Day 
for the Evaluation of Patients at Risk for Venous 
Thromboembolism in the Acute Hospital Care 
Setting) study[1] demonstrated that, globally, more 
than 50% of hospitalised patients are at risk of 
venous thromboembolism (VTE). However, adequate prophylaxis, 
as defined by the 7th American College of Chest Physicians (ACCP) 
guidelines,[2] was given to only approximately 58% of surgical 
patients and 40% of medical patients. The proportion of patients 
likely to benefit from receiving adequate VTE prophylaxis now 
needs to be determined.
The TUNE­IN (The Use of VTE prophylaxis in relatioN to 
patiEnt risk profiling) study[3] was conducted to evaluate common 
practice in the assessment of VTE risk and concurrent prescription 
of prophylaxis in the private inpatient healthcare setting in Gauteng 
Province, South Africa (SA). The study documented the perceived 
clinical VTE risk, actual VTE risk score according to the modified 
Caprini risk assessment model (RAM) (Table 1), VTE prophylaxis 
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prescribed and mobilisation at varying post­discharge dates. The 
TUNE­IN study was published in the SAMJ in February 2012,[4] with 
the following findings:
• Of the patients, 54.1% were considered to be at risk for VTE on
clinical assessment.
• Concurrent use of a VTE RAM increased this figure to 74.6%.
• Adequate prophylaxis, as per VTE prophylaxis guidelines, was only 
administered to 67.9% of surgical and 70.9% of medical patients
who were at risk of VTE.
The TUNE­IN Wave 2 study was an extension of the original TUNE­
IN to a national level and included public sector hospitals to assess 
whether the results of the original study were reflective of both 
healthcare sectors across SA. In addition, TUNE­IN Wave 2 focused 
exclusively on surgical patients and data were only collected once at 
baseline, with no subsequent mobilisation assessment.
Methods
Settings and patients
The TUNE­IN Wave 2 study enrolled 453 patients in a national, 
prospective, non­interventional, multisite, epidemiological disease 
registry over the period September 2009 ­ October 2010. The patients 
were surgical inpatients at 18 sites in private and public sector 
hospitals across the country. The sites were randomly selected.
Data collection
The perceived clinical VTE risk, VTE risk score according to the 
modified Caprini RAM (Table 1), VTE prophylaxis prescribed and 
surgical subspecialty were documented during a baseline visit.
VTE risk scoring
Treating doctors (surgeons, gynaecologists and anaesthetists) at 
participating sites were asked to evaluate VTE risk clinically, i.e. 
without using any official scoring system. The patients were then 
re­evaluated via an approved RAM (Table 1). This scoring system 
assigns various risk factors a specific value. The total VTE risk is 
then calculated by adding the values and assigns the patient to a 
risk category, i.e. low, moderate, high and highest (Table 2). The 
decision regarding administration of VTE prophylaxis was left to the 
treating doctor. A bleeding risk reminder was also provided (Table 
3). Consecutive patients meeting the entry criteria were enrolled. A 
baseline VTE risk assessment was undertaken and VTE prophylaxis 
documented. No risk factor score for HIV disease was given; however, 
as it poses a significant risk for VTE, it was noted as an additional 
comment wherever relevant.
Patient characteristics
TUNE­IN Wave 2 enrolled 453 surgical inpatients within the allo­
cated time period; this was deemed adequate for statistical analysis. 
The majority of the patients (69.5%) were from the private sector, with 
Table 1. Modified Caprini risk model
Each of the following risk factors represents 1 point:
Age 41 ­ 59 years
Minor surgery planned
History of previous major surgery (<1 month)
Varicose veins
History of inflammatory bowel disease
Swollen legs (current)
Obesity (BMI >30 kg/m2)
Acute myocardial infarction (<1 month)
Congestive heart failure (<1 month)
Sepsis (<1 month)
Serious lung disease incl. pneumonia (<1 month)
Abnormal pulmonary function (COPD)
Medical patient currently on bed rest
Leg plaster cast or brace
Central venous access
Each of the following risk factors represents 2 points:
Age 60 ­ 74 years
Major surgery (>60 minutes)
Arthroscopic surgery (>60 minutes)
Laparoscopic surgery (>60 minutes)
Previous malignancy
Morbid obesity (BMI >40 kg/m2)
Each of the following risk factors represents 3 points:
Age ≥75 years
Major surgery lasting 2 ­ 3 hours
BMI >50 kg/m2 (venous stasis syndrome)
History of SVT, DVT/PE
Family history of DVT/PE
Present cancer or chemotherapy
Congenital thrombophilia
Positive factor V Leiden
Positive prothrombin 20210A
Elevated serum homocysteine
Acquired thrombophilia
Positive lupus anticoagulant
Elevated anticardiolipin antibodies
HIT
Other thrombophilia
Each of the following risk factors represents 5 points:
Elective major lower extremity arthroplasty
Hip, pelvis or leg fracture (<1 month)
Stroke (<1 month)
Multiple trauma (<1 month)
Acute spinal cord injury (paralysis) (<1 month)
Major surgery >3 hours
Continued ...
Table 1. (continued) Modified Caprini risk model 
For women only (each risk factor represents 1 point):
Oral contraceptives or HRT
Pregnancy or postpartum (<1 month)
History of unexplained stillborn infant, recurrent spontaneous
abortion (≥3), premature birth with toxaemia or growth­restricted
infant
BMI = body mass index; COPD = chronic obstructive pulmonary disease; SVT = superficial 
venous thrombosis; DVT/PE = deep­vein thrombosis/pulmonary embolism; HIT = heparin­
induced thrombocytopenia; HRT = hormone replacement therapy. 
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30.5% from the public sector. The inclusion 
criteria for the study were as follows: 
surgical inpatient, ≥18 years old, with signed 
patient informed consent and data release 
consent form available. Patients not meeting 
the inclusion criteria, those currently on 
anticoagulation therapy, e.g. warfarin, and 
pregnant women were excluded.
The mean age of patients in the private 
sector was 50.1 years v. 45.4 in the public 
sector. Interestingly, the patients in the private 
sector had higher weights (77.9 kg v. 70.0 
kg) and body mass indices than the public 
sector patients. The majority of the patients 
were female, with a female/male ratio of 
69:31. Just over half (50.2%) were classified 
as being general surgery patients and 21.8% 
as gynaecological patients. The remainder 
of the patients were distributed across 
various surgical subspecialties including 
orthopaedics (8.0%), vascular surgery (2.5%) 
and urology (2.2%). A significant proportion 
(13.3%) of primarily surgical patients had 
concomitant medical comorbidities.
Statistical analysis
The following were key measurements at the 
once­off baseline assessment: (i) clinical VTE 
risk assessment; (ii) VTE risk assessment with 
the Caprini RAM; (iii) surgical subspecialty; 
and (iv) type, duration and dosage of VTE 
prophylaxis prescribed.
Results and discussion
Before applying the Caprini VTE risk 
factor assessment scale, the treating doctors 
deemed 269 patients (59.4%) to be at risk for 
VTE (private n=149 (47.3%), public n=120 
(87.0%)) and 182 (40.2%) not to be at risk 
(private n=164 (52.1%), public n=18 (13.0%)) 
(Table 4 and Fig. 1). VTE risk assessments 
were not recorded for two private patients. 
The 269 patients clinically assessed as being 
at risk for VTE were assigned the following 
risk levels: ‘low’ risk n=3, ‘moderate’ risk 
n=18, ‘high’ risk n=88, and ‘highest’ risk 
n=160. However, all the patients included 
in the study were at risk to a greater or 
lesser extent as assessed on the Caprini RAM 
(Table 4 and Fig. 1). Applying the RAM 
resulted in an additional 184 patients being 
classified as at risk for VTE.
Reasons for not prescribing 
prophylaxis
Why prophylaxis was not prescribed was 
reported for 91 patients (private n=63, public 
n=28), early mobilisation and low VTE 
risk being the most frequent reasons cited. 
Mobilisation (sometimes early) was reported 
65 times as the reason why prophylaxis was not 
prescribed. ‘Early and aggressive mobilisation’ 
was actually listed as a prophylactic measure 
in the study case report form. Fifteen patients 
in the private and 2 in the public sector were 
assessed as being at risk of bleeding according 
to the bleeding risk assessment (Table 3). 
There was an increased perception of bleeding 
risk in the private sector, probably reflecting 
the fact that a higher proportion of patients 
were on antiplatelet drugs such as aspirin and 
thienopyridines, e.g. clopidogrel. Notably, the 
surgeon scheduled to perform the procedure 
Table 2. Risk levels and recommendation according to risk level
Total risk factor score Incidence of DVT Risk level Prophylaxis regimen
0 ­ 1 <10% Low No specific measures, early 
ambulation
2 10 ­ 20% Moderate ES/GCS, IPC, LDUH or LMWH
3 ­ 4 20 ­ 40% High IPC, LDUH or LMWH
≥5 40 ­ 60% 
(1 ­ 5% mortality) 
Highest Pharmacological LDUH, LMWH, 
warfarin or F­Xa inhibitor alone 
or in combination with ES/GCS 
or IPC
ES/GCS = elastic stockings/graduated compression stockings; IPC = intermittent pneumatic compression; LDUH = low­dose 
unfractionated heparin; LMWH = low­molecular­weight heparin; F­Xa = factor Xa. 
Table 3. Bleeding risk assessment
Has the patient, or a blood relative, ever received medical care for a bleeding tendency, e.g.:
Nose bleeds (epistaxis)
Excessive bleeding after a dental procedure or extraction
Excessive bleeding after trauma or surgery
Excessive bleeding after tonsillectomy
Excessive bleeding during childbirth or during menstruation
Excessive bleeding from minor cuts?
Does the patient bruise easily?
Does the patient have a history of heparin­induced thrombocytopenia?
Is the patient’s platelet count <100 × 109/L or >1 000 × 109/L? 
Is the patient taking aspirin or clopidogrel?
Does the patient have kidney or liver disease?
Is the patient on any medication (such as NSAIDs, and including natural/homeopathic 
medication, e.g. garlic tablets, arnica, Procydin) that increases the risk of bleeding?
NSAIDs = non­steroidal anti­inflammatory drugs.
Table 4. VTE risk assessment of patients before (clinically at risk) and after applying the Caprini RAM
Caprini VTE risk level 
determined on TRFS
Private (N=315) Public (N=138) All (N=453)
Clinically at risk,
n (%)
RAM at risk,
n (%)
Clinically at risk,
n (%)
RAM at risk,
n (%)
Clinically at risk,
n (%)
RAM at risk,
 n (%)
Low (TRFS 0 ­ 1) ­ (0) 15 (4.7) 3 (33.3) 9 (6.5) 3 (12.5) 24 (5.3)
Moderate (TRFS 2) 6 (12.2) 49 15.6) 12 (63.2) 19 (13.8) 18 (26.5) 68 (15.0)
High (TRFS 3 ­ 4) 46 (39.0) 118 (37.5) 42 (93.3) 45 (32.6) 88 (54.0) 163 (36.0)
Highest (TRFS ≥5) 97 (72.9) 133 (42.2) 63 (96.9) 65 (47.1) 160 (80.1) 198 (43.7)
Total 149 (47.3) 315 (100) 120 (87.0) 138 (100) 269 (59.4) 453 (100)
VTE = venous thromboembolism; RAM = risk assessment model; TRFS = total risk factor score.
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was also the assessor of bleeding risk in the 
private sector. A bias therefore existed to 
prevent postoperative bleeding, and possible 
litigation, in the private sector. Other reasons 
for omitting prophylaxis included need for 
ventilation, surgery in a vulnerable site, e.g. 
the spine, and presence of a haematoma. More 
than one reason for the omission of VTE 
prophylaxis was reported for some patients.
Prophylaxis prescribed
The distribution of patients according to 
healthcare sector, Caprini risk score and 
VTE prophylaxis prescribed is set out in 
Table 5. Percentages were calculated out of 
the sample sizes for private (n=315), public 
(n=138) and all (N=453) patients.
VTE prophylaxis was prescribed to 110 
(79.7%) of the 138 public sector patients, of 
whom 81.4% in the high­risk level and 86.6% 
in the highest­risk level received prophylaxis. 
VTE prophylaxis was prescribed to 305 of 
the 315 private patients (96.8%), of whom 
96.8% in the high­risk level and 98.5% in the 
highest­risk level received prophylaxis.
The chemoprophylaxis regimens differed 
between the private and public sectors, 
possibly owing to availability of preparations 
(reflecting state tenders in the public sector), 
drug cost (unfractionated heparin (UFH) 
costs less than low­molecular­weight heparin 
(LMWH)), and VTE prophylaxis protocols 
in specific medical institutions.
The use of LMWH predominated in the 
private sector, with 92% of patients receiving 
LMWH and the balance (8%) oral factor Xa 
inhibitors. Low­dose UFH was not prescribed 
in the private sector. Conversely, only 67.5% 
of public sector patients received LMWH, the 
rest receiving UFH. There was no use of oral 
factor Xa inhibitors in the public sector. The 
LMWH dose was most commonly 40 mg once 
daily in both sectors and that of UFH 5 000 IU 
twice daily. The use of non­chemotherapeutic 
prophylactic VTE prophylaxis was extremely 
limited in both the private and the public 
sectors, with pneumatic stockings being used 
in <3% of patients.
Duration of prophylaxis
The overall duration of prophylaxis across all 
risk levels was 6.5 days and was similar in both 
healthcare sectors. The average duration of 
prophylaxis for high­ and highest­risk patients, 
however, was 4.89 and 7.33 days in the private 
and public sectors, respectively. The longer 
duration of prophylaxis in patients in the high/
highest­risk groups in the public v. the private 
sector probably relates to the longer duration of 
admission in the public sector.
Conclusion
The TUNE­IN Wave 2 registry provided 
valuable insight regarding the use of routine 
patient risk assessment in surgical inpatients 
in both the private and the public sectors. 
The registry determined that all the surgical 
inpatients in the study population were at 
risk of VTE to some extent. Doctors do 
not routinely formally risk­assess patients, 
and use of a formal RAM increases their 
awareness of patient risk. The results of 
this study mirror those of the TUNE­IN 
study, confirming the Caprini RAM to be 
applicable across all healthcare sectors in SA.
Before applying the Caprini RAM, the 
admitting doctors clinically diagnosed only 
269 (59.4%) of the patients to be at risk for 
VTE. Public sector patients were clinically 
assessed as being at risk for VTE more 
commonly than those in the private sector 
(87.0% v. 47.3%). However, all the patients 
in the study were at risk to a greater or lesser 
extent as assessed on the RAM.
After applying the Caprini RAM, VTE 
prophylaxis was prescribed to 415 (91.6%) 
of the 453 patients in the study. Prophylaxis 
was prescribed for 92.9% of the patients 
in the high­risk category and to 94.6% of 
those in the highest­risk category. A greater 
percentage of patients across all risk levels 
in the private v. the public sector received 
prophylaxis (96.8% v. 79.7%), possibly owing 
to availability of chemoprophylaxis drug 
preparations, costs and VTE prophylaxis 
protocols. Despite all the patients in the 
study being at risk to some extent, 8.4% 
did not receive any form of prophylaxis. 
Assessment of VTE risk as being low was 
the most frequent reason for not prescribing 
prophylaxis in both healthcare sectors.
Early and aggressive mobilisation con­
tinues to be seen as an active form of VTE 
prophylaxis in both sectors. It was the sole 
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Fig. 1. VTE risk assessment: clinical v. RAM TRFS (VTE = venous thromboembolism; RAM = risk 
assessment model; TRFS = total risk factor score.)
Table 5. VTE prophylaxis according to the Caprini RAM
Caprini VTE risk level 
determined on TRFS
Private
(N=315)
Public
(N=138)
All
(N=453)
Patients, n (%)
Prophylaxis 
prescribed, n (%)* Patients, n (%)
Prophylaxis 
prescribed, n (%)* Patients, n(%)
Prophylaxis 
prescribed, n (%)*
Low (TRFS 0 ­ 1) 11 (3.5) 9 (81.8) 9 (6.5%) 2 (22.2) 20 (2.4) 11 (55.0)
Moderate (TRFS 2) 42 (13.3) 40 (95.2) 19 (13.8) 15 (78.9) 61 (13.5) 55 (90.2)
High (TRFS 3 ­ 4) 125 (39.7) 121 (96.8) 43 (31.2) 35 (81.4) 168 (37.1) 156 (92.9)
Highest (TRFS ≥5) 137 (43.5) 135 (98.5) 67 (48.5) 58 (86.6) 204 (45.0) 193 (94.6)
Total 315 (100) 305 (96.8) 138 (100) 110 (79.7) 453 (100) 415 (91.6)
VTE = venous thromboembolism; RAM = risk assessment model; TRFS = total risk factor score.
*Percentages of patients according to Caprini RAM levels in whom prophylaxis was prescribed. 
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form of prophylaxis in 47.6% of the private and 20.3% of the public 
sector patients. Chemoprophylaxis prescribed included LMWH, low­
dose UFH and oral factor Xa inhibitors, and was prescribed to 41.6% 
of the private and 58.7% of the public sector patients with or without 
concomitant use of graduated compression stockings or intermittent 
pneumatic compression.
The recommended doses of chemo prophylaxis in VTE prophylaxis 
guidelines appear to be being adhered to in both sectors. Forty milli­
grams of LMWH daily and 5 000 IU UFH twice daily were the doses 
most commonly prescribed. The average duration of prophylaxis across 
all risk levels was similar in the two sectors (6.2 days in the private and 7.0 
days in the public sector), with an overall average of 6.5 days.
There is room for improvement in both the public and the private 
sectors with respect to identifying and assessing patients at risk of VTE, 
as well as provision of correct prophylaxis. The implementation of a 
formalised VTE risk assessment tool will benefit patients and ensure 
standardisation of VTE risk assessment and administration of adequate 
prophylaxis.
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